You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-711-ESGO Association of PET-CT tumor metabolic metrics and intraepithelial and stromal tumor-infiltrating lymphocytes in locally advanced cervical cancer prior to concurrent chemo-radiotherapy

Article Text

Article menu

Download PDFPDF

Cervical cancer
2022-RA-711-ESGO Association of PET-CT tumor metabolic metrics and intraepithelial and stromal tumor-infiltrating lymphocytes in locally advanced cervical cancer prior to concurrent chemo-radiotherapy
Free
  1. Alejandra Martinez1,
  2. Mathilde Del1,
  3. Claire Illac2,
  4. Martina Aida Angeles1,
  5. Anne Ducassou3,
  6. Sarah Bétrian4,
  7. Guillaume Bataillon2,
  8. Gwénaël Ferron1,
  9. Stéphanie Motton1,
  10. Amélie Lusque5 and
  11. Erwan Gabiache6
  1. 1Department of Surgical Oncology, Institut Universitaire du Cancer de Toulouse – Oncopole, Toulouse, France
  2. 2Department of Anatomopathology, Institut Universitaire du Cancer de Toulouse – Oncopole, Toulouse, France
  3. 3Department of Radiotherapy, Institut Universitaire du Cancer de Toulouse – Oncopole, Toulouse, France
  4. 4Department of Oncology, Institut Universitaire du Cancer de Toulouse – Oncopole, Toulouse, France
  5. 5Biostatistics Unit, Institut Universitaire du Cancer de Toulouse – Oncopole, Toulouse, France
  6. 6Department of Nuclear Medicine, Institut Universitaire du Cancer de Toulouse – Oncopole, Toulouse, France

Abstract

Introduction/Background Literature data suggests an association between PET/CT metabolic metrics and tumor microenvironment in several malignancies, and a potential role of PET/CT to monitor response to immunotherapy. The aim of the study is to evaluate the correlation between PET/CT tumor metabolic metrics and tumor-infiltrating lymphocytes (TILs) infiltration in locally advanced cervical cancer (LACC) prior to concurrent chemo-radiotherapy.

Methodology Patients with LACC and negative para-aortic extensions on the PET/CT were included. Two senior nuclear medicine physicians specialising in gynaecologic oncology reviewed all PET/CT exams, and extracted tumour SUVmax, MTV, and TLG, as well as pelvic lymph node (PLN) involvement. One senior gynecologic oncology pathologist assessed intraepithelial (iTILs) and stromal tumor-infiltrating lymphocytes (sTILs).

Results 86 patients were included in the analysis. High iTILs and sTILs were identified in 29 (34.9%) and 26 (30.2%) patients, respectively. iTILs and sTILs were non significantly associated with tumor metabolic metrics. A high sTILs score was significantly associated with PLN uptake (61.5% compared to 31.7% in low sTILs, p=0.009). Tumors with low iTILs score were significantly associated with a higher magnetic resonance imaging (MRI) tumor size (≥median) (63.3% versus 39.3%, p=0.042). Low iTILs score was also higher in patients with lymph node aortic involvement (14.8% versus 3.4%).

Abstract 2022-RA-711-ESGO Figure 1
Abstract 2022-RA-711-ESGO Figure 1

Stromal tumor-infiltrating lymphocytes (sTILS) and lymph node PET/CT uptake

Conclusion Poor or absent iTILs was associated with a more advanced disease at diagnosis, with larger tumor size, and more frequent para-aortic lymph node extension. Intraepithelial and stroma TILs are not redundant and should be assessed separately. Further work is needed to evaluate the association between tumor metabolic profile and immune populations, including different T-cell subtypes.

https://doi.org/10.1136/ijgc-2022-ESGO.50

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.